However, semaglutide is not without risks; ongoing research is needed to clarify its potential long-term implications, including its role in pancreatic health; a total of 3073 pancreatic carcinoma cases were associated with GLP-1 RA, with liraglutide showing the strongest signal for pancreatic cancer (ROR 54.45, PRR 52.52) [59]. This evidence concerns the gene GLP1R and exocrine pancreatic carcinoma.